mCRPC Synergy Series: Overcoming Resistance and Optimizing Pathways
24th Feb 2026, 12:30am (GMT)
Free, Online
Global mCRPC Synergy Series: Overcoming Resistance and Optimizing Pathways
25th Feb 2026, 2:00pm (GMT)
Personalized Pathways: Muscle Invasive Bladder Cancer Care 2026
3rd Mar 2026, 12:30am (GMT)
HER2+ MBC Updates from San Antonio Breast Cancer Symposium 2025
Updated 19 Jan 2026
Optimizing Maintenance in HER2+ Metastatic Breast Cancer: A thread
Updated 15 Jan 2026
1L HER2+ / HR+ MBC: Integration Map
Updated 20 Jan 2026
Key Clinical Summary: BRAF-driven treatment decisions - The patient perspective
Updated 22 Jan 2026
Key Clinical Summary: BRAF-driven treatment decisions - Biomarker testing in practice
Key Clinical Summary: BRAF-driven treatment decisions - First line personalization and adverse events management
Key Clinical Summary: Optimizing Maintenance in HER2+ Metastatic Breast Cancer
Key Clinical Summary: The Role of Endocrine Therapy ± CDK4/6 Inhibitors in HER2+/HR+ MBC 1L Setting
Key Clinical Summary: Evolution and Rationale for Maintenance De-Escalation in 1L HER2⁺ MBC
Key Clinical Summary: Cancer Cachexia Update: Focus on Emerging Therapies
Updated 16 Dec 2025
Key Clinical Summary: Cancer Cachexia – The Patient Perspective
Key Clinical Summary: Cancer Cachexia: Multimodal Interventions and Multidisciplinary Management
Key Clinical Summary: Cancer Cachexia: Early Recognition and Comprehensive Care
Pediatric oncology
Posted by Armish Aziz, 19 Nov 2025, 3 comments
Hello, I'm Armish an aspiring pediatric oncologist .
If anyone is interested in it I would like to make a community driven by same passion.
ER+/HER2- metastatic breast cancer Options for treatment personalization based on resistance patterns and biomarkers
BRAF-Driven Treatment Decisions | First-Line Focus Perspectives: Biomarkers in Action
Duration: 8m 1s
3 months ago
BRAF-Driven Treatment Decisions | First-Line Focus Perspectives: Managing What Matters
